Edition:
United States

Akorn Inc (AKRX.OQ)

AKRX.OQ on NASDAQ Stock Exchange Global Select Market

24.77USD
28 Mar 2017
Change (% chg)

$0.79 (+3.29%)
Prev Close
$23.98
Open
$23.85
Day's High
$24.90
Day's Low
$23.46
Volume
1,260,735
Avg. Vol
521,268
52-wk High
$35.30
52-wk Low
$17.61

Latest Key Developments (Source: Significant Developments)

Akorn receives FDA approval for ephedrine sulfate injection, USP
Thursday, 2 Mar 2017 08:25am EST 

Akorn Inc : Akorn receives FDA approval for ephedrine sulfate injection, USP . Akorn Inc says received approval from FDA for its new drug application for ephedrine sulfate injection, USP 50 mg/ml in 1 ml single dose ampule .Akorn Inc - ephedrine sulfate injection is indicated for "treatment of clinically important hypotension occurring in setting of anesthesia".  Full Article

Akorn Inc reports Q4 gaap earnings per share $0.26
Wednesday, 1 Mar 2017 07:00am EST 

Akorn Inc: Q4 gaap earnings per share $0.26 . expects 2017 adjusted net income per diluted share (non-gaap) $1.53 - $1.72 . Akorn provides fourth quarter and full year 2016 results and outlines full year 2017 guidance . Q4 revenue $284 million versus i/b/e/s view $288 million . Q4 earnings per share view $0.57 -- Thomson Reuters I/B/E/S . Q4 adjusted non-gaap earnings per share $0.58 including items . sees 2017 consolidated revenue, $ 1,010 million- $ 1,060 million . Akorn's guidance includes $30 to $60 million from new product launches of products already approved and those expected to be approved in 2017 . sees 2017 gaap net income per diluted share $0.99 -$1.18 . sees 2017 adjusted net income per diluted share (non-gaap) $1.53- $1.72 .Fy2017 earnings per share view $2.17, revenue view $1.12 billion -- Thomson Reuters I/B/E/S.  Full Article

Akorn receives approval for mycophenolate mofetil for injection, USP
Tuesday, 28 Feb 2017 05:30pm EST 

Akorn Inc :Akorn receives approval for mycophenolate mofetil for injection, USP.  Full Article

Akorn reported Q2 EPS $0.50
Thursday, 4 Aug 2016 07:00am EDT 

Akorn Inc : Q2 GAAP earnings per share $0.50 . Q2 adjusted NON-GAAP earnings per share $0.58 including items . Akorn provides second quarter 2016 results . Q2 revenue $281 million versus i/b/e/s view $273 million . Sees FY 2016 revenue $1.06 billion to $1.08 billion . Q2 earnings per share view $0.55 -- Thomson Reuters I/B/E/S . Expects that full year GAAP earnings per share will be at upper end of previously communicated ranges of $1.56 - $1.66 . Expects that full year NON-GAAP earnings per share will be at upper end of previously communicated ranges of $2.10 - $2.20 . FY2016 earnings per share view $2.15, revenue view $1.08 billion -- Thomson Reuters I/B/E/S .Board of Directors authorizes $200 million stock repurchase program.  Full Article

Akorn Q1 earnings $0.34/shr
Monday, 16 May 2016 04:43pm EDT 

Akorn Inc :Qtrly gaap eps of $0.34.  Full Article

Akorn affirms 2016 net revenue and EPS guidance
Tuesday, 10 May 2016 06:55am EDT 

Akorn Inc : Akorn completes 2014 financial statement restatement and reports audited 2015 and restated 2014 results . Affirms 2016 net revenue and earnings per share guidance .Announced plans to hold its 2016 annual meeting of shareholders on July 1, 2016.  Full Article

Akorn to file annual report for year ended Dec 31, 2015 on May 9
Friday, 6 May 2016 02:50pm EDT 

Akorn Inc :On Monday, May 9, 2016, company plans to file annual report on form 10-K for year ended December 31, 2015.  Full Article

Akorn Appoints Duane A. Portwood as Chief Financial Officer
Tuesday, 13 Oct 2015 05:00pm EDT 

Akorn, Inc:Says Duane A. Portwood, will join Akorn as Executive Vice President and Chief Financial Officer, effective October 30, 2015.Interim Chief Financial Officer Randall Pollard will continue to serve as Senior Vice President, Chief Accounting Officer and Corporate Controller after Portwood's appointment.  Full Article

Akorn Inc Launches Doxercalciferol Injection
Monday, 21 Sep 2015 07:00am EDT 

Akorn Inc:Says It has launched Doxercalciferol Injection Solution, 4 mcg/2 mL in 2mL single-use vials. The launch follows an approval of an abbreviated new drug application for the product from the U.S. Food and Drug Administration on May 7, 2015.  Full Article

Akorn Inc appoints Randy Pollard as Interim Chief Financial Officer
Tuesday, 4 Aug 2015 02:35pm EDT 

Akorn Inc:Announced the appointment of Randall Pollard as Chief Accounting Officer and Interim Chief Financial Officer.Pollard's appointment follows the departure of Timothy Dick, who has elected to step down as Senior Vice President and Chief Financial Officer to pursue other opportunities.  Full Article

More From Around the Web

BRIEF-Akorn Inc's CEO Raj Rai's total compensation for 2016 was $7.2 mln

* Akorn Inc - CEO Raj Rai's total compensation for 2016 was $7.2 million - SEC filing Source text for Eikon: (http://bit.ly/2mkcqHb) Further company coverage: